首页> 外文期刊>Seizure: the journal of the British Epilepsy Association >The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies
【24h】

The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies

机译:五种抗癫痫药对苯二氮卓类耐药性惊厥性癫痫持续状态的相对疗效:已发表研究的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Systematic evaluation of published evidence-base of the efficacy of five antiepileptic drugs - lacosamide, levetiracetam, valproate, phenytoin and phenobarbital - in convulsive benzodiazepine-resistant status epilepticus. Methods Data sources included electronic databases, personal communication, and back tracing of references in pertinent studies. These were prospective and retrospective human studies presenting original data for participants with convulsive benzodiazepine-resistant status epilepticus. Interventions were intravenous lacosamide, levetiracetam, phenobarbital, phenytoin and valproate. Outcome measured is clinically detectable cessation of seizure activity. Level-of-evidence was assessed according to Oxford Centre of Evidence-Based Medicine and The Cochrane Collaboration's Tool for Assessment of Risk. Twenty seven studies (798 cases of convulsive status epilepticus) were identified and 22 included in a meta-analysis. Random-effects analysis of dichotomous outcome of a single group estimate (proportion), with inverse variance weighting, was implemented. Several sources of clinical and methodological heterogeneity were identified. Results Efficacy of levetiracetam was 68.5% (95% CI: 56.2-78.7%), phenobarbital 73.6% (95% CI: 58.3-84.8%), phenytoin 50.2% (95% CI: 34.2-66.1%) and valproate 75.7% (95% CI: 63.7-84.8%). Lacosamide studies were excluded from the meta-analysis due to insufficient data. Conclusion Valproate, levetiracetam and phenobarbital can all be used as first line therapy in benzodiazepine- resistant status epilepticus. The evidence does not support the first-line use of phenytoin. There is not enough evidence to support the routine use of lacosamide. Randomized controlled trials are urgently needed.
机译:目的系统评估五种抗癫痫药(拉考酰胺,左乙拉西坦,丙戊酸盐,苯妥英钠和苯巴比妥)在惊厥性苯二氮卓类耐药性癫痫持续状态中的疗效,该研究已发表的证据基础进行系统评估。方法数据来源包括电子数据库,个人通讯和相关研究中参考文献的回溯。这些是前瞻性和回顾性人体研究,为惊厥性苯二氮卓类药物耐药的癫痫发作参与者提供了原始数据。干预措施为静脉内拉考酰胺,左乙拉西坦,苯巴比妥,苯妥英钠和丙戊酸酯。测量的结果是癫痫发作活动的临床可检测的停止。根据牛津大学循证医学中心和Cochrane合作组织的风险评估工具对证据水平进行了评估。确定了27项研究(798例惊厥性癫痫持续状态),其中22项纳入荟萃分析。进行了单组估计二分结果(比例)的随机效应分析,并采用了方差逆加权。确定了临床和方法学异质性的几种来源。结果左乙拉西坦的功效为68.5%(95%CI:56.2-78.7%),苯巴比妥73.6%(95%CI:58.3-84.8%),苯妥英50.2%(95%CI:34.2-66.1%)和丙戊酸盐75.7%( 95%CI:63.7-84.8%)。由于缺乏足够的数据,Lacosamide研究被排除在荟萃分析之外。结论丙戊酸,左乙拉西坦和苯巴比妥均可作为苯二氮卓类耐药性癫痫持续状态的一线治疗方法。证据不支持苯妥英钠的一线使用。没有足够的证据支持常规使用拉可酰胺。迫切需要随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号